TNFRSF8 and mature T-cell and NK-cell non-Hodgkin lymphoma: As previously mentioned, the potential benefit of adding duvelisib to CHOP or CHOEP will be explored as a part of the ALLIANCE/Intergroup A051902 study for previously untreated CD30-negative PTCL.